Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Outcome of lamivudine-resistant hepatitis B virus is generally benign except in cirrhotics.

World journal of gastroenterology - 28 Jul 2005

Dan Yock-Young, Wai Chun-Tao, Lee Yin-Mei, Sutedja Dede-Selamat, Seet Bee-Leng, Lim Seng-Gee

Abstract excerpt

AIM: We set to determine factors that determine clinical severity after the development of resistance. METHODS: Thirty-five Asian patients with genotypic lamivudine resistance were analyzed in three groups: 13/35 (37%) were non-cirrhotics with normal pre-treatment ALT (Group IA), 12/35 (34%) were non-cirrhotics with elevated pre-treatment ALT (Group IB), and 10/35 (29%) were cirrhotics (Group II). Patients were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B, Chronic

Share to Hepatitis B virus

Share to Lamivudine

Share to Liver Cirrhosis

Share to Reverse Transcriptase Inhibitors

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 16038032
DOI: 10.3748/wjg.v11.i28.4344
PMCID: PMC4434660

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Outcome of lamivudine-resistant hepatitis B virus is generally benign except in cirrhotics.PMID 16038032Read ↗

Lamivudine resistance in patients with chronic hepatitis B: Role of clinical and virological factorsSemantic proximity Read ↗

Lamivudine monotherapy in chronic hepatitis B patients from the Indian subcontinent: antiviral resistance mutations and predictive factors of treatment response.Semantic proximity Read ↗

Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan.Semantic proximity Read ↗

Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection.Semantic proximity Read ↗

Clinical characteristics and chronicity of acute hepatitis B induced by lamivudine-resistant strains.Semantic proximity Read ↗

Lamivudine resistance in untreated chronic hepatitis B patients in Turkey.Semantic proximity Read ↗

Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants.Semantic proximity Read ↗

The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment.Semantic proximity Read ↗

The effect of pretransplantation lamivudine resistance on the prognosis of liver transplant recipients.Semantic proximity Read ↗

HBV genotype B/C and response to lamivudine therapy: a systematic review.Semantic proximity Read ↗

Prognosis of 153 patients with decompensated hepatitis B virus-related cirrhosis is improved after 3-year continuous lamivudine treatment.Semantic proximity Read ↗

Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.